Jefferies on MapLight Therapeutics (MPLT): 'there are still several positives to consider'
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $34.00 price target on MapLight Therapeutics (NASDAQ: MPLT).The analyst comments "ML-007C-MA's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
